Thie	B:C1120149
no	I:C1120149
[	I:C1120149
2,3	I:C1120149
-	I:C1120149
b]	I:C1120149
pyridine	I:C1120149
derivatives	O
:	O
a	O
new	O
class	O
of	O
antiviral	O
drugs	I:C0003451
against	O
Mayaro	O
virus	I:C0318738
.	O

Thie	O
no	I:C1120149
[	I:C1120149
2,3	I:C1120149
-	I:C1120149
b]	I:C1120149
pyridine	I:C1120149
derivatives	B:C0243072
:	O
a	O
new	O
class	O
of	O
antiviral	O
drugs	I:C0003451
against	O
Mayaro	O
virus	I:C0318738
.	O

Thie	O
no	I:C1120149
[	I:C1120149
2,3	I:C1120149
-	I:C1120149
b]	I:C1120149
pyridine	I:C1120149
derivatives	O
:	O
a	O
new	O
class	O
of	O
antiviral	B:C0003451
drugs	I:C0003451
against	O
Mayaro	O
virus	I:C0318738
.	O

Thie	O
no	I:C1120149
[	I:C1120149
2,3	I:C1120149
-	I:C1120149
b]	I:C1120149
pyridine	I:C1120149
derivatives	O
:	O
a	O
new	O
class	O
of	O
antiviral	O
drugs	I:C0003451
against	O
Mayaro	B:C0318738
virus	I:C0318738
.	O

Mayaro	B:C0318738
virus	I:C0318738
(	O
Mayaro	O
virus	I:C0318738
)	O
is	O
an	O
arthropod	O
-	I:C0003725
borne	I:C0003725
virus	I:C0003725
and	O
a	O
member	O
of	O
the	O
family	O
Togaviridae	O
,	O
genus	O
Alphavirus	O
.	O

Mayaro	O
virus	I:C0318738
(	O
Mayaro	B:C0318738
virus	I:C0318738
)	O
is	O
an	O
arthropod	O
-	I:C0003725
borne	I:C0003725
virus	I:C0003725
and	O
a	O
member	O
of	O
the	O
family	O
Togaviridae	O
,	O
genus	O
Alphavirus	O
.	O

Mayaro	O
virus	I:C0318738
(	O
Mayaro	O
virus	I:C0318738
)	O
is	O
an	O
arthropod	B:C0003725
-	I:C0003725
borne	I:C0003725
virus	I:C0003725
and	O
a	O
member	O
of	O
the	O
family	O
Togaviridae	O
,	O
genus	O
Alphavirus	O
.	O

Mayaro	O
virus	I:C0318738
(	O
Mayaro	O
virus	I:C0318738
)	O
is	O
an	O
arthropod	O
-	I:C0003725
borne	I:C0003725
virus	I:C0003725
and	O
a	O
member	O
of	O
the	O
family	B:C2700055
Togaviridae	O
,	O
genus	O
Alphavirus	O
.	O

Mayaro	O
virus	I:C0318738
(	O
Mayaro	O
virus	I:C0318738
)	O
is	O
an	O
arthropod	O
-	I:C0003725
borne	I:C0003725
virus	I:C0003725
and	O
a	O
member	O
of	O
the	O
family	O
Togaviridae	B:C0040360
,	O
genus	O
Alphavirus	O
.	O

Mayaro	O
virus	I:C0318738
(	O
Mayaro	O
virus	I:C0318738
)	O
is	O
an	O
arthropod	O
-	I:C0003725
borne	I:C0003725
virus	I:C0003725
and	O
a	O
member	O
of	O
the	O
family	O
Togaviridae	O
,	O
genus	B:C1708235
Alphavirus	O
.	O

Mayaro	O
virus	I:C0318738
(	O
Mayaro	O
virus	I:C0318738
)	O
is	O
an	O
arthropod	O
-	I:C0003725
borne	I:C0003725
virus	I:C0003725
and	O
a	O
member	O
of	O
the	O
family	O
Togaviridae	O
,	O
genus	O
Alphavirus	B:C0002331
.	O

Its	O
infection	B:C3714514
leads	O
to	O
an	O
acute	O
illness	O
accompanied	O
by	O
long	O
-	O
lasting	O
arthralgia	O
.	O

Its	O
infection	O
leads	O
to	O
an	O
acute	O
illness	O
accompanied	O
by	O
long	O
-	O
lasting	O
arthralgia	B:C0003862
.	O

To	O
date	O
,	O
there	O
are	O
no	O
antiviral	B:C0003451
drugs	I:C0003451
or	O
vaccines	O
against	O
infection	O
with	O
Mayaro	O
virus	I:C0318738
and	O
resources	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
other	O
alphaviruses	O
are	O
very	O
limited	O
.	O

To	O
date	O
,	O
there	O
are	O
no	O
antiviral	O
drugs	I:C0003451
or	O
vaccines	B:C0042210
against	O
infection	O
with	O
Mayaro	O
virus	I:C0318738
and	O
resources	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
other	O
alphaviruses	O
are	O
very	O
limited	O
.	O

To	O
date	O
,	O
there	O
are	O
no	O
antiviral	O
drugs	I:C0003451
or	O
vaccines	O
against	O
infection	B:C3714514
with	O
Mayaro	O
virus	I:C0318738
and	O
resources	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
other	O
alphaviruses	O
are	O
very	O
limited	O
.	O

To	O
date	O
,	O
there	O
are	O
no	O
antiviral	O
drugs	I:C0003451
or	O
vaccines	O
against	O
infection	O
with	O
Mayaro	B:C0318738
virus	I:C0318738
and	O
resources	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
other	O
alphaviruses	O
are	O
very	O
limited	O
.	O

To	O
date	O
,	O
there	O
are	O
no	O
antiviral	O
drugs	I:C0003451
or	O
vaccines	O
against	O
infection	O
with	O
Mayaro	O
virus	I:C0318738
and	O
resources	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
other	O
alphaviruses	B:C0002331
are	O
very	O
limited	O
.	O

Mayaro	B:C0318738
virus	I:C0318738
has	O
served	O
as	O
a	O
model	O
to	O
study	O
the	O
antiviral	O
potential	O
of	O
several	O
substances	O
on	O
alphavirus	O
replication	O
.	O

Mayaro	O
virus	I:C0318738
has	O
served	O
as	O
a	O
model	O
to	O
study	B:C2603343
the	O
antiviral	O
potential	O
of	O
several	O
substances	O
on	O
alphavirus	O
replication	O
.	O

Mayaro	O
virus	I:C0318738
has	O
served	O
as	O
a	O
model	O
to	O
study	O
the	O
antiviral	O
potential	O
of	O
several	O
substances	B:C1254351
on	O
alphavirus	O
replication	O
.	O

Mayaro	O
virus	I:C0318738
has	O
served	O
as	O
a	O
model	O
to	O
study	O
the	O
antiviral	O
potential	O
of	O
several	O
substances	O
on	O
alphavirus	B:C0002331
replication	O
.	O

Mayaro	O
virus	I:C0318738
has	O
served	O
as	O
a	O
model	O
to	O
study	O
the	O
antiviral	O
potential	O
of	O
several	O
substances	O
on	O
alphavirus	O
replication	B:C0042774
.	O

In	O
this	O
work	O
we	O
evaluated	O
the	O
antiviral	O
effect	O
of	O
seven	O
new	O
derivatives	B:C0243072
of	O
thie	O
no	I:C1120149
[	I:C1120149
2,3	I:C1120149
-	I:C1120149
b]	I:C1120149
pyridine	I:C1120149
against	O
Mayaro	O
virus	I:C0318738
replication	O
in	O
a	O
mammalian	O
cell	O
line	I:C0007634
.	O

In	O
this	O
work	O
we	O
evaluated	O
the	O
antiviral	O
effect	O
of	O
seven	O
new	O
derivatives	O
of	O
thie	B:C1120149
no	I:C1120149
[	I:C1120149
2,3	I:C1120149
-	I:C1120149
b]	I:C1120149
pyridine	I:C1120149
against	O
Mayaro	O
virus	I:C0318738
replication	O
in	O
a	O
mammalian	O
cell	O
line	I:C0007634
.	O

In	O
this	O
work	O
we	O
evaluated	O
the	O
antiviral	O
effect	O
of	O
seven	O
new	O
derivatives	O
of	O
thie	O
no	I:C1120149
[	I:C1120149
2,3	I:C1120149
-	I:C1120149
b]	I:C1120149
pyridine	I:C1120149
against	O
Mayaro	B:C0318738
virus	I:C0318738
replication	O
in	O
a	O
mammalian	O
cell	O
line	I:C0007634
.	O

In	O
this	O
work	O
we	O
evaluated	O
the	O
antiviral	O
effect	O
of	O
seven	O
new	O
derivatives	O
of	O
thie	O
no	I:C1120149
[	I:C1120149
2,3	I:C1120149
-	I:C1120149
b]	I:C1120149
pyridine	I:C1120149
against	O
Mayaro	O
virus	I:C0318738
replication	B:C0042774
in	O
a	O
mammalian	O
cell	O
line	I:C0007634
.	O

In	O
this	O
work	O
we	O
evaluated	O
the	O
antiviral	O
effect	O
of	O
seven	O
new	O
derivatives	O
of	O
thie	O
no	I:C1120149
[	I:C1120149
2,3	I:C1120149
-	I:C1120149
b]	I:C1120149
pyridine	I:C1120149
against	O
Mayaro	O
virus	I:C0318738
replication	O
in	O
a	O
mammalian	B:C0024660
cell	O
line	I:C0007634
.	O

In	O
this	O
work	O
we	O
evaluated	O
the	O
antiviral	O
effect	O
of	O
seven	O
new	O
derivatives	O
of	O
thie	O
no	I:C1120149
[	I:C1120149
2,3	I:C1120149
-	I:C1120149
b]	I:C1120149
pyridine	I:C1120149
against	O
Mayaro	O
virus	I:C0318738
replication	O
in	O
a	O
mammalian	O
cell	B:C0007634
line	I:C0007634
.	O

All	O
derivatives	B:C0243072
were	O
able	O
to	O
reduce	O
viral	O
production	I:C0042774
effectively	O
at	O
concentrations	O
that	O
were	O
non-toxic	O
for	O
Vero	O
cells	I:C0042542
.	O

All	O
derivatives	O
were	O
able	O
to	O
reduce	O
viral	B:C0042774
production	I:C0042774
effectively	O
at	O
concentrations	O
that	O
were	O
non-toxic	O
for	O
Vero	O
cells	I:C0042542
.	O

All	O
derivatives	O
were	O
able	O
to	O
reduce	O
viral	O
production	I:C0042774
effectively	O
at	O
concentrations	O
that	O
were	O
non-toxic	O
for	O
Vero	B:C0042542
cells	I:C0042542
.	O

Molecular	B:C0005507
modeling	I:C0005507
assays	I:C0005507
predicted	O
low	O
toxicity	O
risk	O
and	O
good	O
oral	O
bioavailability	O
of	O
the	O
substances	O
in	O
humans	O
.	O

Molecular	O
modeling	I:C0005507
assays	I:C0005507
predicted	O
low	O
toxicity	B:C0600688
risk	O
and	O
good	O
oral	O
bioavailability	O
of	O
the	O
substances	O
in	O
humans	O
.	O

Molecular	O
modeling	I:C0005507
assays	I:C0005507
predicted	O
low	O
toxicity	O
risk	O
and	O
good	O
oral	B:C0442027
bioavailability	O
of	O
the	O
substances	O
in	O
humans	O
.	O

Molecular	O
modeling	I:C0005507
assays	I:C0005507
predicted	O
low	O
toxicity	O
risk	O
and	O
good	O
oral	O
bioavailability	O
of	O
the	O
substances	B:C1254351
in	O
humans	O
.	O

Molecular	O
modeling	I:C0005507
assays	I:C0005507
predicted	O
low	O
toxicity	O
risk	O
and	O
good	O
oral	O
bioavailability	O
of	O
the	O
substances	O
in	O
humans	B:C0086418
.	O

One	O
of	O
the	O
molecules	B:C1254351
,	O
selected	O
for	O
further	O
study	O
,	O
demonstrated	O
a	O
strong	O
anti-MAYV	O
effect	O
at	O
early	O
stages	O
of	O
replication	O
,	O
as	O
it	O
protected	O
pre-treated	O
cells	I:C0007634
and	O
also	O
during	O
the	O
late	O
stages	O
,	O
affecting	O
virus	O
morphogenesis	O
.	O

One	O
of	O
the	O
molecules	O
,	O
selected	O
for	O
further	O
study	B:C2603343
,	O
demonstrated	O
a	O
strong	O
anti-MAYV	O
effect	O
at	O
early	O
stages	O
of	O
replication	O
,	O
as	O
it	O
protected	O
pre-treated	O
cells	I:C0007634
and	O
also	O
during	O
the	O
late	O
stages	O
,	O
affecting	O
virus	O
morphogenesis	O
.	O

One	O
of	O
the	O
molecules	O
,	O
selected	O
for	O
further	O
study	O
,	O
demonstrated	O
a	O
strong	O
anti-MAYV	O
effect	O
at	O
early	O
stages	O
of	O
replication	B:C0042774
,	O
as	O
it	O
protected	O
pre-treated	O
cells	I:C0007634
and	O
also	O
during	O
the	O
late	O
stages	O
,	O
affecting	O
virus	O
morphogenesis	O
.	O

One	O
of	O
the	O
molecules	O
,	O
selected	O
for	O
further	O
study	O
,	O
demonstrated	O
a	O
strong	O
anti-MAYV	O
effect	O
at	O
early	O
stages	O
of	O
replication	O
,	O
as	O
it	O
protected	O
pre-treated	B:C0007634
cells	I:C0007634
and	O
also	O
during	O
the	O
late	O
stages	O
,	O
affecting	O
virus	O
morphogenesis	O
.	O

One	O
of	O
the	O
molecules	O
,	O
selected	O
for	O
further	O
study	O
,	O
demonstrated	O
a	O
strong	O
anti-MAYV	O
effect	O
at	O
early	O
stages	O
of	O
replication	O
,	O
as	O
it	O
protected	O
pre-treated	O
cells	I:C0007634
and	O
also	O
during	O
the	O
late	O
stages	O
,	O
affecting	O
virus	B:C0042776
morphogenesis	O
.	O

One	O
of	O
the	O
molecules	O
,	O
selected	O
for	O
further	O
study	O
,	O
demonstrated	O
a	O
strong	O
anti-MAYV	O
effect	O
at	O
early	O
stages	O
of	O
replication	O
,	O
as	O
it	O
protected	O
pre-treated	O
cells	I:C0007634
and	O
also	O
during	O
the	O
late	O
stages	O
,	O
affecting	O
virus	O
morphogenesis	B:C0026559
.	O

This	O
study	B:C2603343
is	O
the	O
first	O
to	O
demonstrate	O
the	O
antiviral	O
effect	O
of	O
thienopyridine	O
derivatives	O
on	O
Mayaro	O
virus	I:C0318738
replication	O
in	O
vitro	O
,	O
suggesting	O
the	O
potential	O
application	O
of	O
these	O
substances	O
as	O
antiviral	O
molecules	I:C0003451
against	O
alphaviruses	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
the	O
antiviral	O
effect	O
of	O
thienopyridine	B:C1120149
derivatives	O
on	O
Mayaro	O
virus	I:C0318738
replication	O
in	O
vitro	O
,	O
suggesting	O
the	O
potential	O
application	O
of	O
these	O
substances	O
as	O
antiviral	O
molecules	I:C0003451
against	O
alphaviruses	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
the	O
antiviral	O
effect	O
of	O
thienopyridine	O
derivatives	B:C0243072
on	O
Mayaro	O
virus	I:C0318738
replication	O
in	O
vitro	O
,	O
suggesting	O
the	O
potential	O
application	O
of	O
these	O
substances	O
as	O
antiviral	O
molecules	I:C0003451
against	O
alphaviruses	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
the	O
antiviral	O
effect	O
of	O
thienopyridine	O
derivatives	O
on	O
Mayaro	B:C0318738
virus	I:C0318738
replication	O
in	O
vitro	O
,	O
suggesting	O
the	O
potential	O
application	O
of	O
these	O
substances	O
as	O
antiviral	O
molecules	I:C0003451
against	O
alphaviruses	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
the	O
antiviral	O
effect	O
of	O
thienopyridine	O
derivatives	O
on	O
Mayaro	O
virus	I:C0318738
replication	B:C0042774
in	O
vitro	O
,	O
suggesting	O
the	O
potential	O
application	O
of	O
these	O
substances	O
as	O
antiviral	O
molecules	I:C0003451
against	O
alphaviruses	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
the	O
antiviral	O
effect	O
of	O
thienopyridine	O
derivatives	O
on	O
Mayaro	O
virus	I:C0318738
replication	O
in	O
vitro	O
,	O
suggesting	O
the	O
potential	O
application	O
of	O
these	O
substances	B:C1254351
as	O
antiviral	O
molecules	I:C0003451
against	O
alphaviruses	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
the	O
antiviral	O
effect	O
of	O
thienopyridine	O
derivatives	O
on	O
Mayaro	O
virus	I:C0318738
replication	O
in	O
vitro	O
,	O
suggesting	O
the	O
potential	O
application	O
of	O
these	O
substances	O
as	O
antiviral	B:C0003451
molecules	I:C0003451
against	O
alphaviruses	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
the	O
antiviral	O
effect	O
of	O
thienopyridine	O
derivatives	O
on	O
Mayaro	O
virus	I:C0318738
replication	O
in	O
vitro	O
,	O
suggesting	O
the	O
potential	O
application	O
of	O
these	O
substances	O
as	O
antiviral	O
molecules	I:C0003451
against	O
alphaviruses	B:C0002331
.	O

Additional	O
in	B:C1515655
vivo	I:C1515655
research	O
will	O
be	O
needed	O
to	O
expand	O
the	O
putative	O
therapeutic	O
applications	O
.	O

Additional	O
in	O
vivo	I:C1515655
research	B:C0035168
will	O
be	O
needed	O
to	O
expand	O
the	O
putative	O
therapeutic	O
applications	O
.	O

